Awaiting an approval on a bone cancer medication(Junovan) . It is sitting near 52 week low's at the moment, but last time the company was waiting on the possible approval the stock tripled. It might be worth a little DD. I took a little nibble today.

The company already seems to have a possible leg up with approval in Europe. Also many more drugs in the future pipeline, so it is not a one man show here. One is a promising skin cancer drug. in phase 2. August 26th is the final FDA hearing on Junovan. I got in early ahead of the anticipation.

here is a lin to the websitehttp://www.idm-biotech.com/index.jsp?workspace=108

IDM Pharma Inc. (IDM) is a biopharmaceutical company focused on developing products to treat and control cancer. IDM?s principal product candidate, Junovan (mifamurtide for injection), known as Mepact in Europe, is part of a family of immunotherapeutic agents that are designed to destroy residual cancer cells by activating the body?s natural defenses. As of December 31, 2006, the Company was developing Junovan for the treatment of osteosarcoma, the most common type of bone cancer. This rare, aggressive bone tumor principally affects adolescents and young adults. Junovan has received orphan drug designation in the United States and the European Union for this indication, permitting it to benefit from a set of laws encouraging the development of treatments for rare diseases. IDM has an agreement with Novartis granting it a worldwide license to intellectual property rights relating to Junovan.

Sector: Healthcare Industry: Biotechnology & Drugs
IDMI 2.64 up0.05 1.93% 250,030 7-19-07

Here's a link about the drug itself.
http://www.drugs.com/nda/junovan_061026.html

I also found this little bit of information on fool.com:

"The committee is also evaluating IDM Pharma's (Nasdaq: IDMI) experimental cancer drug Junovan, for the combination treatment of a type of bone cancer that occurs mostly in adolescents and young adults, and will report on whether it recommends it to the FDA on May 9. When Junovan is combined with other chemotherapy treatments, the probability of survival at six years is 77% for the drug versus 66% without it, which the company says is clinically meaningful because longer survival equates to a better chance of a cure. Given the company's very low float of around 10 million shares and the stock's recent upswing, an endorsement from the committee could bring further upside. However, it should be noted that the trial data IDM Pharma submitted differs from that published by the Children's Oncology Group (in a study supported by the National Cancer Institute). The company believes its data will be adequate, based on discussions with the FDA, and I would put the odds of an endorsement at about 60% because of the young patient population and Junovan's potential survival benefit."

Page Ranking out today

At 52 week low. If you are a bottom troll, maybe now is a good entry. I jumped in a little soon. Tentative approval is Aug 26th. I will sell into the news if given the opportunity.

Will be hot if they get approval. However, having worked in the drug biz for 10 years, one never knows what the FDA is going to do. Approval/rejection will happen when FDA pleases....so it's good that you're ready.

__________________
Disclaimer: Any stocks I comment on are my opinion only. Play the stock market at your own risk!
My Bottom Plays: EVERYTHING!
Get your g00ve on with ALPHATRADE for FREE!
SMC - THE BEST STOCK MARKET FORUM
Pro Bottomfeeder
"A government big enough to give you everything you need, is big enough to take everything you have." - Thomas Jefferson